The FDA White Oak Campus, headquarters of the U.S. Food and Drug Administration
Dr. Richard Pazdur will lead the the U.S. Food and Drug Administration main drug division
The division lost about 1,000 staff this year amid turnover and morale concerns
Pazdur, a 26-year veteran of the agency, is known for speeding up cancer drug approvals
THURSDAY, Nov. 13, 2025 (HealthDay News) — The U.S. Food and Drug Administration (FDA) has appointed one of its most respected cancer drug regulators to lead the agency’s main division for approving new drugs.
The appointment of Dr. Richard Pazdur comes after a turbulent year with hundreds of staff departures within the agency.
Pazdur, who has been with FDA for 26 years, is known for helping speed the approval of lifesaving cancer drugs.
His new role places him at the helm of the Center for Drug Evaluation and Research (CDER), which oversees most prescription and over-the-counter drugs.
“I’m honored to lead CDER at a time when the FDA is achieving long-sought regulatory reforms,” Pazdur said.
He said he looked forward to helping “our country reach its peak in drug development.”
The CDER has about 5,000 employees, down about 1,000 this year due to dismissals, buyouts and resignations.
Pazdur’s predecessor, Dr. George Tidmarsh, resigned recently after being placed on leave during an inspector general investigation. Tidmarsh, a former biotech executive, criticized the FDA’s fast-track approval system and faced a lawsuit from a pharmaceutical company over alleged conflicts; claims he denied.
Pazdur’s appointment was widely seen as a stabilizing choice. He became a champion for faster drug access after his wife, Mary, died of cancer in 2015, The New York Times reported.
He supported the use of “surrogate endpoints” — measures like tumor shrinkage — to speed the approval of promising treatments rather than waiting years to prove longer survival.
That approach has since extended beyond cancer to include rare and neurological diseases.
But Pazdur has also urged drugmakers to withdraw medications that failed to show real benefit after fast-tracked approval.
He has also pressed companies that test cancer drugs in China to repeat trials with U.S. patients.
More information
Learn more about the role of the U.S. Food and Drug Administration.
SOURCE: The New York Times, Nov. 11, 2025
Dr. Richard Pazdur’s new role could speed up future drug approvals.
Originally published on healthday.com, part of the BLOX Digital Content Exchange.
Information from the News and our advertisers (Want to add your business to this to this feed?)
Success! An email has been sent to with a link to confirm list signup.
Error! There was an error processing your request.
Sign up to receive notifications when a new Columbia Gorge News e-Edition is published.
Would you like to receive our news updates? Signup today!
Receive weekly updates on obituaries and death notices.
Oregon Capital Press presented by Columbia Gorge News
Receive updates on upcoming promotions and special sections.
Receive weekly updates on local sports news.
Sorry, there are no recent results for popular videos.
Sorry, an error occurred.
Already Subscribed!
Cancel anytime
Thank you .
Your account has been registered, and you are now logged in.
Check your email for details.
Submitting this form below will send a message to your email with a link to change your password.
An email message containing instructions on how to reset your password has been sent to the email address listed on your account.
No promotional rates found.
Secure & Encrypted
Thank you.
Your gift purchase was successful! Your purchase was successful, and you are now logged in.
| Rate: | |
| Begins: | |
| Transaction ID: |
A receipt was sent to your email.
Commented
Sorry, there are no recent results for popular commented articles.